| 1. |
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation, 2022, 145(8): e153-e639.
|
| 2. |
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation, 2023, 148(9): e9-e119.
|
| 3. |
Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation, 2020, 141(19): e779-e806.
|
| 4. |
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J, 2020, 41(3): 407-477.
|
| 5. |
周奇, 邢丹, 李沁原, 等. 指南解读类文献报告规范的制订指南(RIGHTforINT). 中国循证医学杂志, 2022, 22(5): 497-507.
|
| 6. |
Patel KK, Spertus JA, Chan PS, et al. Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization. Eur Heart J, 2020, 41(6): 759-768.
|
| 7. |
Danad I, Raijmakers PG, Driessen RS, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve. JAMA Cardiol, 2017, 2(10): 1100-1107.
|
| 8. |
Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J, 2008, 29(4): 480-489.
|
| 9. |
Maron DJ, Hochman JS. Invasive or conservative strategy for stable coronary disease. Reply. N Engl J Med, 2020, 383(10): e66.
|
| 10. |
BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med, 2009, 360(24): 2503-2515.
|
| 11. |
Sawicki CM, Jacques PF, Lichtenstein AH, et al. Whole- and refined-grain consumption and longitudinal changes in cardiometabolic risk factors in the framingham offspring cohort. J Nutr, 2021, 151(9): 2790-2799.
|
| 12. |
Rees K, Takeda A, Martin N, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2019, (3): CD009825.
|
| 13. |
Dibben GO, Dalal HM, Taylor RS, et al. Cardiac rehabilitation and physical activity: systematic review and meta-analysis. Heart, 2018, 104(17): 1394-1402.
|
| 14. |
Cornelissen VA, Fagard RH, Coeckelberghs E, et al. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension, 2011, 58(5): 950-958.
|
| 15. |
Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev, 2021, (4): CD010216.
|
| 16. |
Jackson CD, Carter J, Kansagara D. E-Cigarettes versus nicotine replacement therapy for smoking cessation : Hajek P, Phillips-waller A, Przulj D, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019; 380(7): 629-637. J Gen Intern Med, 2021, 36(5): 1481-1483.
|
| 17. |
Saeidifard F, Wang Y, Medina-Inojosa JR, et al. Multicomponent cardiac rehabilitation and cardiovascular outcomes in patients with stable angina: a systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes, 2021, 5(4): 727-741.
|
| 18. |
Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 2007, 356(15): 1503-1516.
|
| 19. |
Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA, 1999, 281(20): 1927-1936.
|
| 20. |
Ohman EM. Clinical practice. Chronic stable angina. N Engl J Med, 2016, 374(12): 1167-1176.
|
| 21. |
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324(7329): 71-86.
|
| 22. |
Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J, 2015, 36(20): 1252-1263.
|
| 23. |
O'Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Circulation, 2020, 142(6): 538-545.
|
| 24. |
Di Mario C, Mugelli A, Perrone Filardi P, et al. Long-term dual antiplatelet therapy: pharmacological and clinical implications. J Cardiovasc Med (Hagerstown), 2018, 19(8): 399-410.
|
| 25. |
Lopes RD, Alexander KP, Stevens SR, et al. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction: insights from the ISCHEMIA trial. Circulation, 2020, 142(18): 1725-1735.
|
| 26. |
Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation, 2020, 141(9): 781-783.
|
| 27. |
Joo SJ, Kim SY, Choi JH, et al. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother, 2021, 7(6): 475-482.
|
| 28. |
Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J, 2002, 143(2): 301-307.
|
| 29. |
Bangalore S, Bhatt DL, Steg PG, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes, 2014, 7(6): 872-881.
|
| 30. |
Bangalore S, Steg G, Deedwania P, et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA, 2012, 308(13): 1340-1349.
|
| 31. |
王增武, 刘静, 李建军, 等. 中国血脂管理指南(2023年). 中国循环杂志, 2023, 38(3): 237-271.
|
| 32. |
Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA, 2019, 322(18): 1780-1788.
|
| 33. |
Zhao SP, Yu BL, Peng DQ, et al. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial. Atherosclerosis, 2014, 233(2): 707-712.
|
| 34. |
Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med, 2023, 388(15): 1353-1364.
|
| 35. |
McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol, 2021, 6(2): 148-158.
|
| 36. |
Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation, 2019, 139(17): 2022-2031.
|
| 37. |
Panico C, Bonora B, Camera A, et al. Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review. Cardiovasc Diabetol, 2023, 22(1): 164.
|
| 38. |
Balogh DB, Wagner LJ, Fekete A. An overview of the cardioprotective effects of novel antidiabetic classes: focus on inflammation, oxidative stress, and fibrosis. Int J Mol Sci, 2023, 24(9): 7789.
|
